Valirx (VAL) RNS Announcements

Add to Alert list
Date Time Source Announcement
13 Sep 2016 07:00 AM
RNS
Quarterly Update on Clinical Developments
02 Sep 2016 02:10 PM
RNS
Placing, issue of warrants & Convertible Loan
11 Aug 2016 07:00 AM
RNS
ValiSeek Clinical Development Update
04 Aug 2016 11:32 AM
RNS
Issue of Equity
28 Jul 2016 07:00 AM
RNS
Notification of New Zealand Patent Grant Allowance
26 Jul 2016 07:00 AM
RNS
Issue of Equity and Bracknor Facility Update
14 Jul 2016 07:00 AM
RNS
ValiSeek Clinical Development Update
12 Jul 2016 11:58 AM
RNS
Result of GM
07 Jul 2016 07:00 AM
RNS
Sale of TRAC Technology Rights for EUR 0.8 million
27 Jun 2016 07:00 AM
RNS
Notice of GM
20 Jun 2016 02:24 PM
RNS
Result of AGM
07 Jun 2016 07:00 AM
RNS
Quarterly Update
07 Jun 2016 07:00 AM
RNS
Appointment of Joint Broker
26 May 2016 08:00 AM
RNS
Posting of Annual Report & Notice of AGM
19 May 2016 11:00 AM
RNS
Final Results
19 May 2016 07:00 AM
RNS
ValiSeek Clinical Development Update
18 May 2016 04:45 PM
RNS
Conversion of Loan Note, issue of warrant & equity
29 Apr 2016 07:00 AM
RNS
Notification of US Patent Grant for VAL401
26 Apr 2016 12:07 PM
RNS
Issue of Equity
22 Apr 2016 10:01 AM
RNS
ValiRx to exhibit at the UK Investor Show
19 Apr 2016 03:32 PM
RNS
Issue of Equity - conversion of loan note
18 Apr 2016 05:00 PM
RNS
Issue of Equity - conversion of loan note
01 Apr 2016 03:10 PM
RNS
Conversion of Loan Note, issue of warrant & equity
31 Mar 2016 07:00 AM
RNS
ValiRx to exhibit and present at the AACR
21 Mar 2016 07:00 AM
RNS
Convertible Loan Facility of up to £4.0 million
17 Mar 2016 07:00 AM
RNS
ValiRx engages US investor relations firm
17 Feb 2016 01:00 PM
RNS
Placing to raise £0.5 million
16 Feb 2016 07:00 AM
RNS
VAL201 Clinical Trial Update
09 Feb 2016 07:00 AM
RNS
Quarterly Update on Clinical Progress
11 Dec 2015 09:30 AM
RNS
ValiRx to present at Shares Investor Meeting
19 Nov 2015 10:45 AM
RNS
Clinical Phase Development Update
05 Nov 2015 07:00 AM
RNS
ValiRx establishes US office in Boston, MA
27 Oct 2015 07:00 AM
RNS
Collaboration Agreement
01 Oct 2015 07:00 AM
RNS
New Japanese Patent Grant
17 Sep 2015 12:15 PM
RNS
Half Yearly Report
16 Sep 2015 07:00 AM
RNS
Subscription and Equity Swap
06 Aug 2015 07:00 AM
RNS
Collaboration and Research Studentship Agreement
21 Jul 2015 07:00 AM
RNS
VAL201 Clinical Trial Update
16 Jul 2015 07:00 AM
RNS
ValiSeek Clinical Development Update
29 Jun 2015 07:00 AM
RNS
Grant of options
25 Jun 2015 07:00 AM
RNS
UPDATE on VAL201 Clinical Trial
03 Jun 2015 07:00 AM
RNS
Change of Adviser
27 May 2015 11:22 AM
RNS
Stmnt re Share Price Movement
15 May 2015 02:45 PM
RNS
Result of AGM and Capital Reorganisation
14 May 2015 03:50 PM
RNS
Notification of US Patent Grant Allowance reVAL401
14 May 2015 07:00 AM
RNS
ValiSeek Development Update
07 May 2015 07:00 AM
RNS
Re Contract
30 Apr 2015 07:00 AM
RNS
ValiRX to attend 2015 BIO International Convention
22 Apr 2015 07:00 AM
RNS
Notice of AGM and Proposed Capital Reorganisation
16 Apr 2015 07:00 AM
RNS
Final Results

ValiRx PLC: A Biotech Innovator on the London Stock Exchange (LSE)

ValiRx PLC, known by its ticker symbol VAL, is a trailblazer in the biotechnology sector. Its performance on the London Stock Exchange (LSE) has been remarkable, with the ValiRx share price reflecting the company's consistent growth and success.

As a member of the LSE, ValiRx PLC aligns with the London Stock Exchange Group's (LSEG) mission of supporting innovative and growing businesses. The LSEG recognises ValiRx PLC as a significant player, contributing to the robust and diverse ecosystem of the LSE.

The ValiRx share price on the LSE not only underscores its financial stability but also its strategic vision in the biotechnology industry. ValiRx PLC's journey on the LSE is a testament to its robust business model and its ability to create value for its stakeholders.

In conclusion, ValiRx PLC's association with the LSE and LSEG symbolises its commitment to growth, innovation, and value creation. As ValiRx PLC continues to thrive on the LSE, it sets the bar high for the biotechnology industry, contributing to the dynamic and diverse ecosystem of the LSEG. With its focus on cancer therapeutics, ValiRx is a key player in the healthcare sector, making strides in medical research and development.

UK 100

Latest directors dealings